Compare PepsiCo, Inc. (PEP) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
PepsiCo, Inc. vs State Street SPDR S&P Biotech ETF — how do they compare? PepsiCo, Inc. trades at $126.12 (market cap $174.89B), while State Street SPDR S&P Biotech ETF trades at $153.87 (market cap $10.11B). The key difference: PepsiCo, Inc. is far larger — about 17.3× State Street SPDR S&P Biotech ETF's market cap, and PepsiCo, Inc. pays a 4.61% dividend while State Street SPDR S&P Biotech ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold PepsiCo, Inc. for 107 Days and State Street SPDR S&P Biotech ETF for 38 Days on average.
| PEP | XBI | |
|---|---|---|
Market Cap | $174.89B | $10.11B |
Volume | 23,968,864 | 12,903,266 |
Sector | Consumer Staples | Broad Market / Factor |
52-Week High | $170.44 | $169.55 |
52-Week Low | $123.64 | $104.99 |
Typical Hold Time | 107 Days | 38 Days |
Enterprise Value | $215.61B | — |
Dividend Yield | 4.61% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
PepsiCo (PEP) trades at $125.80, up 1.74% today, with a bearish technical signal but strong fundamentals including four consecutive quarterly EPS beats. Revenue grew to $93.93B in 2025, with a net margin of 10.78% and robust cash flow. Analyst consensus is a Buy with a $146.77 price target, though recent news highlights pricing pressures in snacks.
The outlook is mixed: strong profitability and institutional support offer upside, but bearish technicals and consumer pushback on high prices pose near-term risks. Execution on North American turnaround and margin expansion will be critical for sustained growth amid competitive and macroeconomic challenges.
XBI trades at $153.84, up 2.4% today, but technical indicators signal a bearish trend with resistance at $154. The ETF's modified equal-weight structure offers broad biotech exposure, benefiting from M&A activity and positive clinical catalysts, though key financial ratios are unavailable. Recent news highlights sector optimism driven by cancer vaccine breakthroughs and improved capital access.
Outlook is mixed: bullish sentiment from innovation and M&A supports growth potential, but high volatility and expense ratios relative to peers pose risks. Analyst consensus is neutral (100% Hold), suggesting cautious optimism amid technical bearishness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About PepsiCo, Inc.
PepsiCo is one of the largest food and beverage companies globally. It makes, markets, and sells a slew of brands across the beverage and snack categories, including Pepsi, Mountain Dew, Gatorade, Doritos, Lays, and Ruffles. The firm uses a largely integrated go-to-market model, though it does leverage third-party bottlers, contract manufacturers, and distributors in certain markets. In addition to company-owned trademarks, Pepsi manufactures and distributes other brands through partnerships and joint ventures with companies such as Starbucks. The firm segments its operations into five primary geographies, with North America (comprising Frito-Lay North America, Quaker Foods North America, and North America beverages) constituting around 60% of consolidated revenue.
Read more on PEP →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
